Standard and Interpretation
Expert consensus on the management of diabetic patients with cardiovascular diseases
National Health Commissim Capacity Buiding and Continuing Education Center, Sun Yihong, Chen Kang, Chen Xin, Gu Weijun, Guo Yuanlin, Li Yijun, Liu Tong, Peng Daoquan, Mu Yiming, Ma Changsheng
Published 2021-05-01
Cite as Chin J Intern Med, 2021, 60(5): 421-437. DOI: 10.3760/cma.j.cn112138-20201208-00999
Abstract
Diabetes is the most important comorbidity of cardiovascular disease, and cardiovascular disease is the main cause of mortality and disability of patients with type 2 diabetes. In order to standardize the diagnosis and treatment of patients with diabetes and cardiovascular disease, the National Health Commission Capacity Building and Continuing Education Center organized the experts from the field of cardiology and endocrinology systematically reviewing the research progresses and expert experiences of relevant disciplines from home and abroad, and formulated this consensus. This consensus covers the diagnosis, drug treatment, and risk factor management for patients with diabetes and cardiovascular disease (including atherosclerotic cardiovascular disease and heart failure) from the perspective of cardiovascular disease and diabetes management aiming to strengthen the comprehensive management of patients and ultimately to improve the prognosis of patients. The management of cardiovascular diseases mainly includes the management of blood pressure, blood lipids, anti-thrombosis, anti-myocardial ischemia, anti-ventricular remodeling and so on. Diabetes management mainly includes lifestyle intervention (including diet, exercise, weight loss, etc.), anti-hyperglycemia therapy (including drugs and insulin), blood glucose monitoring, and hypoglycemic prevention. In addition, specific clinical recommendations are given to patients with special health care needs such as diabetic nephropathy, elderly (>75 years), and cardiovascular critical illness.
Key words:
Diabetes mellitus; Coronary heart disease; Heart failure; Blood pressure; Blood lipid; Anti-hyperglycemic treatment
Contributor Information
National Health Commissim Capacity Buiding and Continuing Education Center
Sun Yihong
Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China
Chen Kang
Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Chen Xin
Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
Gu Weijun
Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Guo Yuanlin
Department of Cardiology, Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China
Li Yijun
Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Liu Tong
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Center for Cardiovascular Diseases, Beijing 100029, China
Peng Daoquan
Department of Cardiology, the Second Xiangya Hospital of Central South University, Changsha 410011, China
Mu Yiming
Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Ma Changsheng
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Center for Cardiovascular Diseases, Beijing 100029, China